NishantTagejaMD

Oncology • Greensburg, PA

Physician

Join to view full profile

Dr. Tageja is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tageja's full profile

Already have an account?

Office
200 Village Dr
Greensburg, PA 15601
Phone+1 724-838-1900

Fax+1 724-838-5620

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2008 - 2011
Delhi University College of Medical SciencesClass of 2006

Certifications & Licensure

PA State Medical License 2017 - 2024
WV State Medical License 2014 - 2019
MI State Medical License 2008 - 2018
OH State Medical License 2016 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

100 citations
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde, Mattias Carlsten, Min-Jung Lee, Alex Minter, Esther Tan
Haematologica. 2014-06-01
242 citations
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Neha Korde, Mark Roschewski, Adriana Zingone, Mary Kwok, Elisabet E. Manasanch
JAMA Oncology. 2015-09-01
13 citations
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering ...
Dickran Kazandjian, Elizabeth M. Hill, Alexander Dew, Candis Morrison, Joseph Roswarski
JAMA Oncology. 2021-11-01

Lectures

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

UPMC Begins Administering Additional Dose of Covid-19 for ImmunocompromisedAugust 13th, 2021